Comparing Vanguard Healthcare ETF and iShares Biotechnology ETF
The Vanguard Healthcare ETF (VHT) and the iShares Biotechnology ETF (IBB) present two different approaches to investing in the health sector. One emphasizes broader sector diversification, while the other hones in on high-growth biotech areas. This might be useful for investors trying to decide where they fit in—balancing between widespread coverage and focused exposure.
Your choice of these funds will depend on how much volatility you’re willing to handle and what kind of growth you’re looking for in a specific subsector. The healthcare landscape is diverse, ranging from stable pharmaceutical giants to speculative biotech startups. Weighing these options will help clarify the trade-offs between a holistic healthcare strategy and a targeted biotech strategy, guiding you toward what aligns best with your financial aspirations.
Snapshots (cost and size)
| Metric | IBB | VHT |
|---|---|---|
| Publisher | iShares | Vanguard |
| Stock price (as of July 1, 2026) | $190.12 | $300.84 |
| Expense ratio | 0.44% | 0.09% |
| 1-year return (as of July 1, 2026) | 49.3% | 21.8% |
| Dividend yield | 0.2% | 1.6% |
| Assets | $9.5 billion | $19 billion |
Note: Beta measures volatility against the S&P 500, calculated from five years of monthly returns. One-year return indicates total yield over the next twelve months, and dividend yield reflects the trailing 12-month distribution yield.
When it comes to costs, Vanguard’s fund tends to be more favorable for long-term investors, boasting a cost differential of 0.35 percentage points in its expense ratio compared to the iShares ETF. Over many years, this can significantly impact overall returns. If income generation is a priority, VHT offers a healthy dividend yield, while IBB focuses more on capital appreciation.
Performance and Risk Comparison
| Metric | IBB | VHT |
|---|---|---|
| Maximum drawdown (5 years) | (39.8%) | (17.7%) |
| $1,000 growth in 5 years (total return) | $1,170 | $1,291 |
What’s Inside
The Vanguard fund employs a passive management style to reflect the healthcare sector’s performance overall. Its top holdings include strong players like Eli Lilly at 14.01%, Johnson & Johnson at 8.45%, and AbbVie at 6.08%. With 429 different holdings, the fund spreads its capital across various industries, which can help mitigate risks associated with downturns in any particular area. Established in 2004, VHT distributed $4.72 per share over the last twelve months, yielding about 1.6% based on its recent stock price of $300.84.
On the other hand, iShares zeroes in on publicly traded biotech firms. Key holdings include Vertex Pharmaceuticals at 8.1%, Amgen at 7.81%, and Gilead Sciences at 6.82%. This fund houses 248 holdings focusing on cutting-edge genetic research and drug development. While such specialization could lead to higher returns during biotech upswings, it also increases exposure to regulatory and trial uncertainties. Launched in 2001, IBB distributed $0.41 per share in the last year, amounting to a yield of 0.2% based on its recent price of $190.12.
What This Means for Investors
Generally speaking, IBB is likely more appealing to aggressive investors, whereas VHT suits those with a more conservative outlook. IBB includes prominent firms like Amgen, Biogen, and Moderna among its top ten holdings. However, focusing solely on biotech may mean that it contains smaller, less proven companies, which can elevate risk. Many burgeoning biotechs have only one or two products in development, making their success rather uncertain. Larger biotech companies tend to have several candidates in the pipeline that can help lower risk.
